Get the Stockscreener App
3.45
10.93%
0.34
After Hours:
3.45
Lantern Pharma Inc stock is traded at $3.45, with a volume of 22,773.
It is up +10.93% in the last 24 hours and down -9.69% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.11
Open:
$3.14
24h Volume:
22,773
Relative Volume:
0.29
Market Cap:
$37.96M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-1.9382
EPS:
-1.78
Net Cash Flow:
$-17.24M
1W Performance:
-1.99%
1M Performance:
-9.69%
6M Performance:
+1.77%
1Y Performance:
-39.69%
1-Day Range:
$3.07
$3.50
1-Week Range:
$3.00
$3.71
52-Week Range:
$2.55
$7.21
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.45 | 37.96M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges - Investing.com Australia
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
Lantern Pharma : Announces Upcoming Conference Presentations - MarketScreener
Lantern Pharma (NASDAQ:LTRN) Research Coverage Started at Lake Street Capital - The AM Reporter
Lake Street Capital Begins Coverage on Lantern Pharma (NASDAQ:LTRN) - Defense World
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - Nasdaq
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navi - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks
Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - 01net
LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa
Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus
Lantern Pharma Inc Qtrly EPS $-0.54 - MarketScreener
Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks
Preview: Lantern Pharma's Earnings - Benzinga
Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace
Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - Stock Titan
LTRN: M&A Illuminates GBM Value - Yahoo Finance
Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey
Lantern Pharma advances AI-driven drug development with patent - Investing.com India
Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance
Top 10 AI Stocks Dominating Wall Street - Insider Monkey
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):